Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELECTROCORE, INC.

(ECOR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ElectroCore, Inc. Announces Open Access and Submission of Manuscript from Savior-1 Study of Non-Invasive Vagus Nerve Stimulation in Hospitalized Covid-19 Patients

09/29/2021 | 08:00am EST

electroCore, Inc. announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in patients admitted to the hospital for treatment of COVID-19; is available on MedRxiv and has been submitted for peer review. This study was an investigator-initiated trial conducted at the Hospital Clínico Universitario de Valencia, Spain. The SAVIOR-1 study enrolled 110 patients over 18 years of age between April 2020 and February 2021. A total of 97 patients comprised of 47 treatment subjects and 50 control subjects provided baseline demographic and medical history data. The study was designed to evaluate the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with standard of care alone. The analyses identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein (CRP) levels were significantly greater for the nVNS treatment group as compared to the control group throughout the five-day period combined (p= 0.010) and on day 5 compared to the day 1 baseline period alone (p= 0.012). At day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control (p=0.010). Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 (p=0.004) as compared to the control group. Increased levels of CRP, procalcitonin and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms.


ę S&P Capital IQ 2021
All news about ELECTROCORE, INC.
11/11electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
GL
11/04ELECTROCORE, INC. Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/04ElectroCore, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/04ElectroCore Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04ElectroCore, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year Ending Dec..
CI
11/04Earnings Flash (ECOR) ELECTROCORE Reports Q3 Revenue $1.49M, vs. Street Est of $1.5M
MT
11/04electroCore Announces Third Quarter 2021 Financial Results
GL
10/21ELECTROCORE : to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
GL
10/20ELECTROCORE : Announces Publication Reviewing the Prescribing of gammaCore for the Treatme..
AQ
10/14ELECTROCORE : GammaCore Device Wins Canadian Approval for Treatment of Adolescent Migraine
MT
More news
Analyst Recommendations on ELECTROCORE, INC.
More recommendations
Financials (USD)
Sales 2021 5,53 M - -
Net income 2021 -16,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,42x
Yield 2021 -
Capitalization 49,7 M 49,7 M -
Capi. / Sales 2021 8,98x
Capi. / Sales 2022 5,14x
Nbr of Employees 45
Free-Float 87,9%
Chart ELECTROCORE, INC.
Duration : Period :
electroCore, Inc. Technical Analysis Chart | ECOR | US28531P1030 | MarketScreener
Technical analysis trends ELECTROCORE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,70 $
Average target price 3,15 $
Spread / Average Target 348%
EPS Revisions
Managers and Directors
Daniel S. Goldberger Chief Executive Officer & Director
Brian M. Posner Secretary, Chief Financial & Accounting Officer
F. Peter Cuneo Chairman
Peter S. Staats Chief Medical Officer
Basit Qari Vice President-Information & Digital Technology
Sector and Competitors
1st jan.Capi. (M$)
ELECTROCORE, INC.-52.81%50
MASIMO CORPORATION3.20%15 295
GETINGE AB95.11%11 152
PENUMBRA, INC.39.15%8 894
NOVOCURE LIMITED-47.37%8 519
IRAY TECHNOLOGY COMPANY LIMITED211.61%6 087